Spero Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
SPRO$1.01-5.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEM ENTS OF CASH FLOWS
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $8,572 | $(68,566) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Depreciation and amortization | — | 2 |
| Non-cash lease cost | 1,048 | 1,043 |
| Impairment of assets | 587 | — |
| Share-based compensation | 4,325 | 7,793 |
| Changes in operating assets and liabilities: | ||
| Collaboration receivable, current and non-current - related party | 24,032 | 46,351 |
| Other receivables | 3,057 | (1,540) |
| Prepaid expenses and other current assets | 277 | 2,267 |
| Other assets | — | 282 |
| Accounts payable | (6,613) | 5,928 |
| Accrued expenses and other current liabilities | (12,146) | 11,167 |
| Deferred revenue | (12,587) | (370) |
| Deferred revenue - related party | (22,074) | (26,255) |
| Other long-term liabilities | 91 | (87) |
| Operating lease liabilities | (1,402) | (1,246) |
| Income taxes payable | 209 | (213) |
| Net cash used in operating activities | (12,624) | (23,444) |
| Net decrease in cash and cash equivalents | (12,624) | (23,444) |
| Cash and cash equivalents at beginning of period | 52,889 | 76,333 |
| Cash and cash equivalents at end of period | $40,265 | $52,889 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.